Sleep Apnea and Vascular Function
Trial status: Open for Enrollment
Why is this study being done?
Obstructive sleep apnea (OSA) is associated with endothelial dysfunction and the development of cardiovascular disease. It is unclear how OSA results in endothelial dysfunction, but given the association between OSA and obesity, adipose-derived hormones (adipokines) are likely to be involved. Leptin, an adipokine upregulated in patients with OSA, has been shown to be associated with deleterious effects on vascular function resulting in impaired endothelial function. This proposal is directed at investigating the molecular mechanisms of endothelial dysfunction in OSA patients. We hypothesize that endothelial dysfunction associated with OSA is a result of molecular alterations within endothelial cells. As a part of these studies we will look at NO signaling pathways in adipose tissue and microvessels from normal and OSA subjects.
Who is eligible to participate?
- Non OSA, and newly diagnosed OSA subjects, naïve to CPAP treatment, aged 20-55 years, with BMI less than 40 kg/m2, who are free of all chronic diseases including hypertension, diabetes, and cardiovascular diseases, will be recruited for our study.
- Anemic (hemoglobin <13.5 g/dL for men and <12.0 g/dL for women.
- Use of chronic Medications (aspirin, beta agonist, anti-inflammatory drugs)